Catalyst
Slingshot members are tracking this event:
Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Movement Disorders
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ACOR | Community voting in process |
Additional Information
“Oral levodopa is a cornerstone of Parkinson’s disease treatment, but after chronic therapy, approximately half of people with PD who are treated with oral L-dopa experience OFF periods,” said Peter LeWitt, M.D., M.Med.Sc., Director of the PD and Movement Disorders Program at Henry Ford Hospitaland lead author of the study. “OFF periods tend to increase in frequency, severity and duration during the course of the disease, and are among the most challenging experiences for people with this disorder. Based on the data from this Phase 2b clinical study, CVT-301 has the potential to restore motor function to people with Parkinson’s disease when they experience OFF periods, and this is now being studied in a Phase 3 clinical trial.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b, Cvt-301, Off Periods, Parkinson’s Disease, Movement Disorders